1. MRI prospective survey on cardiac and hepatic iron in transfusion-dependent thalassemia intermedia patients treated with desferrioxamine, deferiprone and deferasirox
- Author
-
Alessia Pepe, Antonino Vallone, Massimiliano Missere, Antonella Meloni, Silvia Macchi, Maria Chiara Resta, Vincenzo Positano, Mari Giovanna Neri, Daniele De Marchi, and Crocetta Argento
- Subjects
Medicine(all) ,medicine.medical_specialty ,Liver Iron Concentration ,Radiological and Ultrasound Technology ,business.industry ,Deferasirox ,Normal MRI ,Gastroenterology ,chemistry.chemical_compound ,chemistry ,hemic and lymphatic diseases ,Internal medicine ,Poster Presentation ,medicine ,Transfusion dependent thalassemia ,Radiology, Nuclear Medicine and imaging ,Hepatic iron ,Cardiology and Cardiovascular Medicine ,Deferiprone ,business ,Prospective survey ,Angiology ,medicine.drug - Abstract
Results Three groups of patients were identified: 27 patients (13 females, mean age 40.12±10.31 years) treated with desferioxamine (DFO mean dosage 37.52±8.69 mg/kg/ die), 23 patients (14 females, mean age 34.73±10.67 years) treated with deferiprone (DFPdosage 71.70 ±14.46mg/kg/die) and 14 patients (9 females, mean age 36.63±10.92 years) treated with deferasirox (DFX mean dosage 27.75±5.04 mg/kg/die). Excellent/good levels of compliance were similar in the DFO (92.6%), DFP (100%) and DFX (100%) groups (P=0.345). The mean starting age of regular transfusion was 14.73 ±15.89 years. At baseline in DFO group two patients (7.4%) showed a global heart T2*
- Published
- 2015
- Full Text
- View/download PDF